| MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer (NCT00072930) | MedImmune LLC | 2003-12-01 |
| Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight (NCT00303875) | Duke University | 2003-12-01 |
| Clinical Trial for Prostate Cancer (NCT00076531) | Oakwood Laboratories, LLC | 2003-12-01 |
| ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases (NCT00294437) | Central European Cooperative Oncology Group | 2003-12-01 |
| Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy (NCT00241475) | AstraZeneca | 2003-12-01 |
| A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy (NCT00087659) | Novartis Pharmaceuticals | 2003-12-01 |
| Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy (NCT00090376) | Eisai Inc. | 2003-12-01 |
| Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer (NCT00132756) | Morton Plant Mease Health Care | 2003-12-01 |
| Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer (NCT00233610) | AstraZeneca | 2003-12-01 |
| Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance. (NCT00584532) | University of California, Davis | 2003-11-01 |
| Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer (NCT00077402) | Cancer Therapeutics Research Group | 2003-11-01 |
| Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer (NCT00084526) | Fox Chase Cancer Center | 2003-11-01 |
| Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer (NCT00084565) | Fox Chase Cancer Center | 2003-11-01 |
| Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy (NCT00237146) | Novartis Pharmaceuticals | 2003-11-01 |
| Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration (NCT00987376) | Mayo Clinic | 2003-11-01 |
| PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy (NCT00078585) | Bavarian Nordic | 2003-11-01 |
| Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer (NCT00027859) | Eastern Cooperative Oncology Group | 2003-10-08 |
| Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy (NCT00129142) | GTx | 2003-10-01 |
| Prostatectomy Prospective Database (NCT00447616) | Kenneth Peters, MD | 2003-10-01 |
| RADAR Trial - Randomised Androgen Deprivation and Radiotherapy (NCT00193856) | Trans Tasman Radiation Oncology Group | 2003-10-01 |
| Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer (NCT00060437) | National Cancer Institute (NCI) | 2003-10-01 |
| Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer (NCT00345813) | Wake Forest University Health Sciences | 2003-10-01 |
| Evaluate Recovery of Testosterone for Patients Using Eligard (NCT01136226) | Chesapeake Urology Research Associates | 2003-10-01 |
| Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer (NCT00104741) | UNICANCER | 2003-09-10 |
| A Study of Pertuzumab in Participants With Prostate Cancer (NCT02480010) | Hoffmann-La Roche | 2003-09-01 |
| Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer (NCT00181584) | Massachusetts General Hospital | 2003-09-01 |
| Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer (NCT00739791) | University of California, San Francisco | 2003-09-01 |
| Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) (NCT00072722) | Celgene Corporation | 2003-09-01 |
| Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer (NCT00219271) | Novartis Pharmaceuticals | 2003-09-01 |
| Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen (NCT00069745) | Agennix | 2003-09-01 |
| Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases (NCT00219219) | Novartis | 2003-09-01 |
| Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse (NCT00071968) | Jonsson Comprehensive Cancer Center | 2003-08-01 |
| Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer (NCT00078910) | National Cancer Institute (NCI) | 2003-08-01 |
| Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer (NCT00258284) | Barbara Ann Karmanos Cancer Institute | 2003-08-01 |
| Analyses of Human Samples Collected in Clinical Trials (NCT00339664) | National Cancer Institute (NCI) | 2003-07-02 |
| Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer (NCT00587431) | Memorial Sloan Kettering Cancer Center | 2003-07-01 |
| Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583 (NCT00898833) | Alliance for Clinical Trials in Oncology | 2003-07-01 |
| Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation (NCT00186420) | Stanford University | 2003-07-01 |
| Positron Emission Tomography in Prostate Cancer (NCT00121212) | Washington University School of Medicine | 2003-07-01 |
| Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy (NCT00065442) | Dendreon | 2003-07-01 |
| Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer (NCT00032058) | American College of Radiology Imaging Network | 2003-06-01 |
| Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer (NCT00063882) | Radiation Therapy Oncology Group | 2003-06-01 |
| Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer (NCT00176579) | University of Medicine and Dentistry of New Jersey | 2003-06-01 |
| Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX (NCT00590213) | AstraZeneca | 2003-06-01 |
| Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer (NCT00500110) | M.D. Anderson Cancer Center | 2003-06-01 |
| Registry and Database Lap Prostatectomy (NCT00169676) | Indiana Kidney Stone Institute | 2003-06-01 |
| Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery (NCT00458549) | Dana-Farber Cancer Institute | 2003-05-27 |
| Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment (NCT00061347) | National Cancer Institute (NCI) | 2003-05-23 |
| A Research Study for Patients With Prostate Cancer (NCT00106418) | Celgene | 2003-05-07 |
| Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer (NCT00242918) | Benaroya Research Institute | 2003-05-01 |
| A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening (NCT00208988) | Emory University | 2003-05-01 |
| Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 (NCT00084825) | M.D. Anderson Cancer Center | 2003-05-01 |
| Markers for Early Detection of Prostate Cancer (NCT00340717) | National Cancer Institute (NCI) | 2003-05-01 |
| Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases (NCT00080678) | M.D. Anderson Cancer Center | 2003-05-01 |
| Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer (NCT00067015) | Memorial Sloan Kettering Cancer Center | 2003-05-01 |
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors (NCT00471432) | NCIC Clinical Trials Group | 2003-04-04 |
| Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain (NCT00082927) | Cancer Research UK | 2003-04-01 |
| Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer (NCT00058539) | Genentech, Inc. | 2003-04-01 |
| Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer (NCT00122265) | AHS Cancer Control Alberta | 2003-04-01 |
| ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body (NCT00061126) | Abgenix | 2003-04-01 |
| Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy (NCT00073970) | UNC Lineberger Comprehensive Cancer Center | 2003-04-01 |
| Study of Aranesp to Treat Anemia in Prostate Cancer Patients. (NCT00245895) | University of Washington | 2003-04-01 |
| Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer (NCT00402285) | University of California, San Francisco | 2003-04-01 |
| The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (NCT00063609) | Novartis Pharmaceuticals | 2003-04-01 |
| Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy (NCT00582556) | University of Wisconsin, Madison | 2003-04-01 |
| Effectiveness of Localized Prostate Cancer Treatments (NCT01492751) | Fundacion IMIM | 2003-04-01 |
| Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men (NCT00761124) | Jonsson Comprehensive Cancer Center | 2003-04-01 |
| Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone (NCT00059631) | M.D. Anderson Cancer Center | 2003-03-20 |
| Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer (NCT00328614) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2003-03-01 |
| Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer (NCT00151047) | University of Michigan Rogel Cancer Center | 2003-03-01 |
| Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer (NCT00061867) | Imunon | 2003-03-01 |
| Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients (NCT00215657) | Ferring Pharmaceuticals | 2003-03-01 |
| Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer (NCT00134654) | Dana-Farber Cancer Institute | 2003-03-01 |
| I-125 Versus Pd-103 for Medium Risk Prostate Cancer (NCT00486499) | VA Puget Sound Health Care System | 2003-03-01 |
| GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer (NCT00400517) | The Cleveland Clinic | 2003-03-01 |
| Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation (NCT00058188) | Northwestern University | 2003-03-01 |
| Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors (NCT00054977) | Galectin Therapeutics Inc. | 2003-02-01 |
| [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer (NCT00588185) | Memorial Sloan Kettering Cancer Center | 2003-02-01 |
| A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer (NCT00122499) | Erasmus Medical Center | 2003-02-01 |
| Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) (NCT00060476) | Merck Sharp & Dohme LLC | 2003-01-08 |
| Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer (NCT00057759) | Radiation Therapy Oncology Group | 2003-01-01 |
| Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer (NCT00859027) | UConn Health | 2003-01-01 |
| Trial of Iressa in Prostate Cancer Patients (NCT00265070) | AstraZeneca | 2003-01-01 |
| Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel (NCT00705835) | Memorial Sloan Kettering Cancer Center | 2003-01-01 |
| Eating, Activity, and Stress Education (NCT01434004) | University of South Carolina | 2003-01-01 |
| Management of Prostate Cancer in Central China (NCT01614548) | Zhengzhou University | 2003-01-01 |
| Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer (NCT00049309) | Duke University | 2003-01-01 |
| Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area (NCT00702104) | University of California, San Francisco | 2003-01-01 |
| Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer (NCT00363285) | St. Bartholomew's Hospital | 2003-01-01 |
| Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients (NCT01823549) | Ohio State University Comprehensive Cancer Center | 2002-12-11 |
| Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer (NCT00054106) | NCIC Clinical Trials Group | 2002-12-10 |
| Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer (NCT00316927) | St. Bartholomew's Hospital | 2002-12-01 |
| Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer (NCT00136526) | University of Washington | 2002-12-01 |
| 3-AP in Treating Patients With Advanced Prostate Cancer (NCT00054015) | Vion Pharmaceuticals | 2002-12-01 |
| Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy (NCT00058266) | Northwestern University | 2002-12-01 |
| Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse (NCT00055731) | UNICANCER | 2002-11-14 |
| Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients (NCT00818623) | Ferring Pharmaceuticals | 2002-11-01 |
| Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer (NCT00054574) | Jonsson Comprehensive Cancer Center | 2002-11-01 |
| Casodex - Nolvadex Combination (NCT00637871) | AstraZeneca | 2002-11-01 |
| Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer (NCT00455624) | Massachusetts General Hospital | 2002-11-01 |